Ads
related to: treatment for psoriatic arthritis- Patient Characteristics
Learn About How Psoriatic Arthritis
Manifests Differently In Patients.
- Risk Of Treatment Delays
Learn How & Why Delay Can Lead To
Further Joint Damage Here.
- Dosing Resources
Learn Now About SC Dosing And
Prescribing Treatment Options.
- Clinical Trial Results
Get Results From A Clinical
Long-term Study Of A Biologic.
- IV Dosing Information
Learn More About IV Dosing &
Administration On The HCP Website.
- Safety Data & Resources
Access Important Information
Regarding Patient Safety Here.
- Patient Characteristics
Search results
Results From The WOW.Com Content Network
The underlying process in psoriatic arthritis is inflammation; therefore, treatments are directed at reducing and controlling inflammation. The first-line initial treatment for most patients is a TNF inhibitor -type biological disease-modifying anti-rheumatic drug (DMARD).
Risankizumab, sold under the brand name Skyrizi (/ s k aɪ ˈ r ɪ z i / sky-RIZZ-ee), is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. [6] [7] It is designed to target interleukin 23A (IL-23A). [6] [7] [9] It is given by subcutaneous injection. [6] [7]
Psoriatic arthritis is a type of arthritis that develops in some people who have psoriasis, which is a chronic autoimmune disease of the skin. ... “There are several good treatment paradigms for ...
Apremilast, sold under the brand name Otezla among others, is a medication for the treatment of certain types of psoriasis and psoriatic arthritis. [4] The drug acts as a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4). [4] It is taken by mouth. [4]
Rheumatoid arthritis (RA) Psoriatic arthritis, which is associated with the skin condition psoriasis ... Surgery is usually only recommended after other arthritis treatments and therapies have ...
In April 2018, guselkumab was approved in Japan for the treatment of psoriatic arthritis. [19] In July 2020, the FDA approved guselkumab as the first IL-23 inhibitor to treat active psoriatic arthritis (PsA). [20] [21] In September 2024, the FDA approved guselkumab for the treatment of moderately to severely active ulcerative colitis in adults. [9]
Ads
related to: treatment for psoriatic arthritis